28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Long-term use of sulfonylureas, thiazolidinediones, or insulin was not associated with an altered risk of developing AD. 3 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
MR-guided focused ultrasound (MRgFUS), in combination with intravenous microbubble administration, has been applied for focal temporary BBB opening in patients with neurodegenerative disorders and brain tumors. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Anticholinergic medication burden in schizophrenia is substantial, common, conferred by multiple medication classes, and associated with cognitive impairments across all cognitive domains. 4 key findings →
Design: cross-sectional Participants: 1,120 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Digital RT proved an innovative approach to manage PWD and will thus help PWD achieve a better mood and have more opportunities to engage in social interactions. 3 key findings →
Participants: 25 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Available data consistently show that risk of progression increases across the preclinical AD stages, where Stage 3 shows a risk of progression comparable to MCI due to AD. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Treatment options for Alzheimer disease (AD) are limited and have focused mainly on symptomatic therapy and improving quality of life. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
What is known Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Reality orientation therapy combined with cholinesterase inhibitors has not been evaluated in patients with Alzheimer's disease. 4 key findings →
Participants: 156 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study reported the generation of aducanumab, a human monoclonal antibody designed to selectively target aggregated Aβ. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Although psychotropic drug use has been associated with increased risk of falls in long-term care settings; this association may be confounded by the high prevalence of dementia and depression and other fall risk factors. 4 key findings →
Design: cohort study Participants: 178 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The innate immune system is a viable target for therapeutic intervention in AD. 5 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
Combinations of plasma and digital cognitive markers show promise for scalable diagnosis and prognosis of ADRD. 1 key finding →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing, affecting around 46 million people worldwide but few treatments are currently available. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Use of metformin, DPP4 inhibitors, GLP1 analogs and SGLT2 inhibitors was associated with lower risk of dementia in patients with diabetes. 3 key findings →
Design: case-control study Participants: 250 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Between October 2021 and June 2022, 53 candidates were assessed; 29 met eligibility criteria and were randomised. 5 key findings →
Design: RCT Participants: 29 Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
Memory loss is one of the first symptoms of typical Alzheimer's disease (AD), for which there are no effective therapies available. 3 key findings →
Participants: 14 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Eight out of 15 patients completed the entire study. 4 key findings →
Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Addition of ATX to ongoing cholinesterase-inhibitor therapy was generally well tolerated but did not significantly improve cognitive function. 5 key findings →
Participants: 92 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In moderate-to-severe Alzheimer disease (AD), there are significant losses of activities of daily living (ADL). 5 key findings →
Participants: 404 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Earlier NH admission of Australian compared to U.K. and U.S. subjects may be due to differences in health care, NH systems, availability, and affordability. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Donepezil and memantine have similar modest clinical and spectroscopic effect on mild to moderate AD. 3 key findings →
Design: randomized controlled trial Participants: 32 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
No registered drug affects the deposition of Aβ in the brain of AD patients. 5 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These responder analyses may assist clinicians in evaluating the impact of memantine in a relevant clinical scenario, i.e., in patients with AD previously stabilized on a cholinesterase inhibitor. 3 key findings →
Participants: 404 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Memantine, an N-methyl-D-aspartate receptor antagonist, is approved in the United States and Europe for the treatment of moderate to severe Alzheimer disease (AD) and has also been investigated in patients with mild to moderate AD. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
10 of the 3,106 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →